News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bayer AG (BAYN.DE) To Inject $700 Million In Hemophilia A Drugs



3/11/2014 10:18:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bayer HealthCare and Kythera announced that Bayer will sell back to Kythera commercial rights to ATX-101 outside of the United States and Canada. In 2010, Bayer licensed these rights from Kythera. ATX-101 is a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat (double chin). Under the new agreement, Bayer will receive $ 33 million in Kythera common stock, plus a $ 51 million promissory note, payable no later than 2024 from KYTHERA. Bayer is also eligible to receive certain long-term sales milestone payments on annual sales outside of the United States and Canada.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES